Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Yi Ning, Yu Zhou, Qi Zhang, Zhi-wei Chen, Yu-qing Huang, Qi Zhang et al. IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib. // Acta Pharmacologica Sinica. – 2026. – DOI: 10.1038/s41401-026-01953-z. – URL: https://www.nature.com/articles/s41401-026-01953-z
Yi Ning, Yu Zhou, Qi Zhang, Zhi-wei Chen, Yu-qing Huang, Qi Zhang, Yun Chen, Wen-hao Shi, Qiu-pei Liu, Ya-ping Xue, Tao Zhang, Jian Ding, Wen-hu Duan, & Hua Xie (2026). IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-026-01953-z
Yi Ning, et al. “IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib.” Acta Pharmacologica Sinica, 2026. doi:10.1038/s41401-026-01953-z.
@article{Ning2026,
title = {IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib},
author = {Ning, Yi and Zhou, Yu and Zhang, Qi and Chen, Zhi-wei and Huang, Yu-qing and Zhang, Qi and Chen, Yun and Shi, Wen-hao and Liu, Qiu-pei and Xue, Ya-ping and Zhang, Tao and Ding, Jian and Duan, Wen-hu and Xie, Hua},
journal = {Acta Pharmacologica Sinica},
year = {2026},
doi = {10.1038/s41401-026-01953-z},
url = {https://www.nature.com/articles/s41401-026-01953-z}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/s41573-026-01583-4 From hope to adoption: an industry perspective on the maturation of new approach methodologies